News | July 14, 2011

Boston Scientific Completes Trial Enrollment for Adapt Monorail Carotid Stent

July 14, 2011 — Boston Scientific Corporation has completed patient enrollment in the ASTI post-market clinical follow-up study evaluating its Adapt monorail carotid stent system in combination with its FilterWire EZ embolic protection system for treatment of carotid artery disease in patients at high risk for carotid surgery.

The trial began in 2010 and has reached its enrollment goal of 100 patients at 11 sites in Europe. Principal investigator of the study is Marc Bosiers, M.D., head of the department of vascular surgery, A.Z. Sint-Blasius Hospital in Dendermonde, Belgium.  

The stent features thin struts and an innovative design engineered for flexibility in the carotid arteries. It incorporates a self-expanding, rolled nitinol sheet with patented dynamic tapering technology designed to conform to varying carotid anatomies. This second-generation carotid stent also provides excellent visibility and has a closed-cell geometry that facilitates consistent lesion coverage. It has been sold in Europe as well as other select countries since receiving CE mark in 2010.  

"The Adapt stent offers outstanding deliverability and scaffolding of the vessel wall, which are critical attributes for carotid stents," said Bosiers. "I look forward to seeing how the features of this new technology may be reflected in clinical outcomes from the ASTI study."

The study will examine rates of major adverse events, defined as any death, stroke or myocardial infarction at 30 days. Additionally, it will assess rates of late ipsilateral stroke, target lesion revascularization and in-stent restenosis.

In addition to the Adapt carotid stent, Boston Scientific markets the Carotid Wallstent Monorail Endoprosthesis. Both stents are mounted on monorail delivery systems and feature closed-cell designs intended to offer increased scaffolding of the vessel wall. Both stents are also designed to be used in conjunction with the FilterWire EZ embolic protection system, intended to capture plaque debris released during the stenting procedure. The Adapt carotid stent system is not available for sale in the United States.  

For more information: www.bostonscientific.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init